Business
Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
– TIME recognizes Dr. Mendell’s decades-long contributions in the treatment of neuromuscular disease and the advancement of gene therapy, including the first
About this update from Sarepta Therapeutics, Inc.
[{"type":"text","content":"\n– TIME recognizes Dr. Mendell’s decades-long contributions in the treatment of neuromuscular disease and the advancement of gene therapy, including the first gene therapy for Duchenne muscular dystrophy\n\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher, physician and gene therapy pioneer Jerry R. Mendell, M.D., to the inaugural 2024 TIME100 Health, a list of 100 individuals who most influenced global health this year. Dr. Mendell was recognized for his lifetime commitment to neuromuscular disease and achievements in genetic medicine that propelled a new age of treatment for several genetic diseases, including Duchenne muscular dystrophy.\n\n\nThe TIME100 Health list recognizes the impact, innovation, and achievement of the world’s most influential individuals in health. TIME selected a community of leaders across industries dedicated to creating tangible and credible change for a healthier population, including pioneering scientists who are steering the evolution of global health in 2024.\n\n\n“Dr. Mendell’s humility and compassion for patients and families shines through his relentless focus on advancing science with the potential to change the course of devastating, fatal and once untreatable neuromuscular diseases,” said Louise Rodino-Klapac, Ph.D., executive vice president, head of R&D and chief scientific officer, Sarepta Therapeutics. “I have had the honor of working with Dr. Mendell for many years, first at Nationwide Children’s Hospital and now at Sarepta, to see some of his life’s work come to fruition. Dr. Mendell’s accomplishments in the field of neuromuscular disease, and the care that he provided to patients and their families in more than 50 years of practice, continue to inspire Sarepta and others working to advance the science of genetic medicine.”\n\n\nDr. Mendell began his career at the U.S. National Institutes of Health, and shortly after he met his first patient living with Duchenne. His early work was followed by decades as a clinician and researcher at Nationwide Children’s Hospital to understand Duchenne’s progressive muscle wasting trajectory and ways to intervene to slow or alter the course of the disease. He is a pioneer in gene therapy for neur...